Design Therapeutics Inc (DSGN) Earnings Report, Financial Results, Financial analysis

Design Therapeutics Inc increased first quarter of 2023 net loss per share of $-0.35 compare to net loss per share of $-0.24 recorded in the same quarter a year ago a decrease compare to $-0.31 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -0.35	$ 0 Mill
$-0.11	Unch.

Design Therapeutics Inc 's Revenue fell by 0 % in first quarter of 2023 (Mar 31 2023) year on year, to $0 million and declined by sequentially.

Design Therapeutics Inc is Expected to report next financial results on August 07, 2023.

More on DSGN's Income Statement

DSGN's NET INCOME

Design Therapeutics Inc 's in thefirst quarter of 2023 recorded net loss of $-19.294 million, an increase from net loss of $-13.265 million in I. Quarter a year ago.

Sequentially net loss advanced

More on DSGN's Growth

Design Therapeutics Inc Inventories
DSGN's Cash flow In thefirst quarter of 2023 company's net cash flow was $2 million, capital expenditures fell by 14.47%, to $0 millions compare to same quarter a year ago and rose by -69.79% from IV. Quarter (Dec 31 2022).

More on DSGN's Cash flow Statement

Earnings quality

Design Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Design Therapeutics Inc payed $ -1.02 cash per share, on a free-cash flow basis .

Book value fell by -5.07 % sequentially to $5.60 per share, -23.96% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.60 per share from $ 5.89.

Company issued 0.37 million shares or 0.67 % in Mar 31 2023.

• More on DSGN's Dividends

Market Capitalization (Millions)	343
Shares Outstanding (Millions)	56
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-69
Cash Flow (TTM) (Millions $)	-259
Capital Exp. (TTM) (Millions $)	-1
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Earnings quality

Design Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Design Therapeutics Inc had negative $ -1.02 cash flow per share, on a free-cash flow basis .

Book value fell by -5.07 % sequentially to $5.60 per share, -23.96% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.60 per share from $ 5.89.

Company issued 0.37 million shares or 0.67 % in Mar 31 2023.

• More on DSGN's Balance Sheets

Market Capitalization (Millions)	343
Shares Outstanding (Millions)	56
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-69
Cash Flow (TTM) (Millions $)	-259
Capital Exp. (TTM) (Millions $)	-1
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Design Therapeutics Inc

DSGN's Financial Statements and Analysis